Palo Alto Networks exceeds expectations in Q3 performance and raises full-year guidance

Third Life World signed a definitive control share purchase agreement to take voting control of Transglobal Management Group (TMGI). The deal transfers a Series A Preferred control block holding a majority of voting rights to Third Life World. TMGI plans to make Third Life World’s AI-agent virtual world platform its core operating business. TMGI will create new Series B Preferred Stock to support the purchase; closing remains subject to customary conditions. At closing, controlling shareholder Marc Angell will resign his officer roles and stay on as a consultant during the transition. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transglobal Management Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610081100PRIMZONEFULLFEED9842281) on October 08, 2026, and is solely responsible for the information contained therein.

October 8 – ** Shares of medical device manufacturer Haemonetics (HAE.N) surged nearly 16% to $117.81 ** The stock hit an intraday high of $120.61, marking its highest level since early 2021 ** The company stated that CSL Plasma, a subsidiary of Australia’s CSL Group (CSL.AX), expects to transition all its U.S. plasma collection centers to using HAE’s NexSys devices and kits by the end of 2027 ** CSL has also terminated its agreement with HAE rival Terumo (Terumo 4543.T) – according to BTIG ** This transition will help HAE win back business lost since 2021, when its largest plasma client CSL announced it would not renew its U.S. supply contract ** BTIG estimates that, based on approximately $155 million in revenue HAE generated from CSL’s U.S. business in fiscal year 2024, this account could add about $0.60 per share to adjusted earnings annually, though it notes that actual revenue and profit margins remain unclear ** The brokerage maintained its “Buy” rating and raised its price target from $110 to $130, stating that the deal alleviates market share loss concerns and boosts sales growth prospects ** Including today’s gains, the stock is up 49.46% so far this year (For the convenience of non-English speakers, Reuters provides its reports in several other languages through automated translation. Because automated translation may be inaccurate or lack needed context, Reuters does not guarantee the accuracy of the automated text, which is offered purely as a reader service. Reuters accepts no liability for any damage or loss caused by the use of automated translation services.)